SCHEMBL15040982

SCHEMBL15040982

Cc1ccc(-c2ccc(F)cn2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.58
ABL1 P00519 1/20 0.58
NTRK1 P04629 1/20 0.58
LCK P06239 1/20 0.58
CSF1R P07333 1/20 0.58
RET P07949 1/20 0.58
MET P08581 1/20 0.58
PDGFRB P09619 1/20 0.58
PIM1 P11309 1/20 0.58
PDGFRA P16234 1/20 0.58
FLT3 P36888 1/20 0.58
MAPK8 P45983 1/20 0.58
CDK8 P49336 1/20 0.58
MAP2K1 Q02750 1/20 0.58
MAP4K2 Q12851 1/20 0.58
ROCK1 Q13464 1/20 0.58
NTRK3 Q16288 1/20 0.58
MAPK14 Q16539 1/20 0.58
AURKB Q96GD4 1/20 0.58
NPC1 O15118 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28873007 0.88 AURKA (0.59) AURKAABL1NTRK1LCKCSF1R
SCHEMBL2997318 0.88 CCR1 (0.60) AURKAABL1NTRK1LCKCSF1R
SCHEMBL2477927 0.82 CCR1 (0.71) AURKAABL1NTRK1LCKCSF1R
SCHEMBL10000248 0.80 CCR1 (0.68) AURKAABL1NTRK1LCKCSF1R
SCHEMBL10000250 0.80 CCR1 (0.54) AURKAABL1NTRK1LCKCSF1R
SCHEMBL13750539 0.80 TDO2 (0.46) AURKAABL1NTRK1LCKCSF1R
SCHEMBL17051514 0.80 CCR1 (0.75) AURKAABL1NTRK1LCKCSF1R
SCHEMBL23253055 0.79 NPC1 (0.49) AURKAABL1NTRK1LCKCSF1R
SCHEMBL12987394 0.79 NPC1 (0.53) METNPC1KDM1ARXFP1BRS3
SCHEMBL2840143 0.79 NPC1 (0.49) AURKAABL1NTRK1LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10403833-B2 Organic metal complexes MERCK PATENT GMBH (DE) 2019-09-03 US disclosed
EP-2856528-B1 METAL COMPLEXES COMPRISING CONDENSED HETEROAROMATIC RINGS MERCK PATENT GMBH (DE) 2019-07-03 EP disclosed
EP-2483263-B1 HETEROCYCLIC COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME (US) 2018-07-18 EP disclosed
US-9879177-B2 Metal complexes comprising condensed heteroaromatic rings MERCK PATENT GMBH (DE) 2018-01-30 US disclosed
US-9879177-B2 Metal complexes comprising condensed heteroaromatic rings MERCK PATENT GMBH (DE) 2018-01-30 US disclosed
US-20170317298-A1 ORGANIC METAL COMPLEXES UDC IRELAND LIMITED (IE) 2017-11-02 US disclosed
US-20170317298-A1 ORGANIC METAL COMPLEXES UDC IRELAND LIMITED (IE) 2017-11-02 US disclosed
US-9748502-B2 Organic metal complexes MERCK PATENT GMBH (DE) 2017-08-29 US disclosed
US-9748502-B2 Organic metal complexes MERCK PATENT GMBH (DE) 2017-08-29 US disclosed
EP-2791275-B1 ORGANIC SENSITIZERS FOR UP-CONVERSION MERCK PATENT GMBH (DE) 2017-05-31 EP disclosed
US-20140350642-A1 Metal Complexes Comprising 1,2,3-Triazoles MERCK PATENT GMBH (DE) 2014-11-27 US disclosed
US-20140350642-A1 Metal Complexes Comprising 1,2,3-Triazoles MERCK PATENT GMBH (DE) 2014-11-27 US disclosed
US-8658651-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2014-02-25 US disclosed
WO-2013174471-A1 METAL COMPLEXES COMPRISING CONDENSED HETEROAROMATIC RINGS MERCK PATENT GMBH (DE) 2013-11-28 WO disclosed
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 US disclosed
WO-2013107487-A1 ORGANIC METAL COMPLEXES MERCK PATENT GMBH (DE) 2013-07-25 WO disclosed
WO-2013097920-A1 METAL COMPLEXES COMPRISING 1,2,3-TRIAZOLES MERCK PATENT GMBH (DE) 2013-07-04 WO disclosed
WO-2013087162-A1 ORGANIC SENSITIZERS FOR UP-CONVERSION MERCK PATENT GMBH (DE) 2013-06-20 WO disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 US disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118284-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPK10 AURKA 780/4885ABL1 76/4885NTRK1 2365/4885
US-10403833-B2 Organic metal complexes SOD1, ORC3, PPIA AURKA 1560/4885ABL1 1985/4885NTRK1 4318/4885
US-20070191604-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 AURKA 589/4885ABL1 76/4885NTRK1 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.